Spain – Antineoplastic agents – The procurement, through a Framework Agreement with a single economic operator, of the successive supply of the advanced therapy medicinal product Lisocabtagene maraleucel, as an individual treatment per patient.
Successive supply of medicinal products for the second-line treatment of diffuse large B-cell lymphoma. The procurement through a Framework Agreement of the successive supply of the advanced therapy medicinal product Lisocabtagene maraleucel, as
Opportunity description
Successive supply of medicinal products for the second-line treatment of diffuse large B-cell lymphoma. The procurement through a Framework Agreement of the successive supply of the advanced therapy medicinal product Lisocabtagene maraleucel, as an individual treatment per patient. Procedure: neg-wo-call. Estimated value: 20,708,160 EUR. Review the original TED notice for the complete requirement, lots, amendments and attachments.
Business details are available after sign in
Codes, capabilities, evidence, buyer details and marketplace actions are withheld from the public HTML and API response.